SLX 3039
Alternative Names: SLX-3039Latest Information Update: 19 Jul 2024
At a glance
- Originator Biolexis Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 9 degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Prostate cancer